Is Bone Biologics Corp (BBLG) Stock a Good Investment? (2024)

Featured Tickers:

BBLG

Learn more about whether Bone Biologics Corp is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how (BBLG) grades on certain investment factors and determine whether it meets your investment needs.

Latest Bone Biologics Corp Stock News

As of January 22, 2024, Bone Biologics Corp had a $1.7 million market capitalization, putting it in the 5th percentile of companies in the Medical Equipment, Supplies & Distribution industry.

Bone Biologics Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Bone Biologics Corp’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-25.840 per share for the current fiscal year. Bone Biologics Corp does not currently pay a dividend.

There has been anincreasein demand for medical devicesin recent years, largely driven byprocess innovations,emerging technologyandan aging population.In2021, the medical equipment industryshouldpositively benefit from coronavirus test sales, new product sales and growingexposure inemerging markets.Companiesselling coronavirus tests are expected to have strong sales for the year aspeople return toofficesand schools.There hasalsobeen progress made by vaccine campaigns. Analysts expect to seearecovery inelective procedure volumes to pre-pandemic levels, which experienced particularly harshheadwindsin 2020 due to the pandemic.As a result, hospitalslikely have a backlog of deferred procedures to work through.However, recovery for the industry could be relatively impacted bythe financial pressures facing consumers,whichmay prevent people from seeking medical attention.In the long term, analysts see positive fundamental trends for medical device manufacturers, including global demand for cost-effective value-based health care, gaining demographics and rising research and development (R&D) investments, which have resulted in a steady stream of innovative products and revenue growth.

Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Bone Biologics Corp Stock

Before you choose to buy, sell or hold Bone Biologics Corp stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (BBLG) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Bone Biologics Corp’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Latest Bone Biologics Corp Stock News

As of January 22, 2024, Bone Biologics Corp had a $1.7 million market capitalization, putting it in the 5th percentile of companies in the Medical Equipment, Supplies & Distribution industry.

Bone Biologics Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Bone Biologics Corp’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-25.840 per share for the current fiscal year. Bone Biologics Corp does not currently pay a dividend.

There has been anincreasein demand for medical devicesin recent years, largely driven byprocess innovations,emerging technologyandan aging population.In2021, the medical equipment industryshouldpositively benefit from coronavirus test sales, new product sales and growingexposure inemerging markets.Companiesselling coronavirus tests are expected to have strong sales for the year aspeople return toofficesand schools.There hasalsobeen progress made by vaccine campaigns. Analysts expect to seearecovery inelective procedure volumes to pre-pandemic levels, which experienced particularly harshheadwindsin 2020 due to the pandemic.As a result, hospitalslikely have a backlog of deferred procedures to work through.However, recovery for the industry could be relatively impacted bythe financial pressures facing consumers,whichmay prevent people from seeking medical attention.In the long term, analysts see positive fundamental trends for medical device manufacturers, including global demand for cost-effective value-based health care, gaining demographics and rising research and development (R&D) investments, which have resulted in a steady stream of innovative products and revenue growth.

Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Bone Biologics Corp Stock

Before you choose to buy, sell or hold Bone Biologics Corp stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (BBLG) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Bone Biologics Corp’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Bone Biologics Corp Stock Growth Grade

Growth Grade:

Metric Metric Score BBLG Sector Median
Sales Growth 5yr Ann'l 0 0.0% 12.3%
Sales Increases YoY Last 5 yrs 0 0 of 5 0 of 5
Cash from Operations Ann'l Positive Last 5 yrs 0 0 of 5 0 of 5

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the Growth Score and assign it a letter grade, the percentile ranks for each of the three individual components‐consistency of annual sales growth, five‐year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered Very Weak, while those in the top 20% receive A grades, which are considered Very Strong.

Bone Biologics Corp has a Growth Score of 0, which is Very Weak.

Don’t Miss Your Free Report — Sign Up Here!

Bone Biologics Corp Stock Momentum Grade

Momentum Grade:

MetricScoreBBLGSector Median
Relative Price Strength (Q1) 16 (33.3%)(6.8%)
Relative Price Strength (Q2) 8 (54.2%)(22.1%)
Relative Price Strength (Q3) 1 (83.2%)(14.0%)
Relative Price Strength (Q4) 33 (19.6%)(15.2%)
Relative Price Strength (weighted 4 qtr) 5 (44.7%)(8.2%)

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Bone Biologics Corp has a Momentum Score of 5, which is Very Weak.

Other Bone Biologics Corp Stock Grades

In addition to Momentum and Growth, A+ Investor also provides grades for Value, Estimate Revisions and Quality.

Invest with Confidence with A+ Investor

AAII’s expansive and robust screening tools like A+ Investor help investors make confident decisions.

The Earnings Estimate Revisions Grade takes into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too). AAII’s stock screen that follows the companies with the highest earnings estimate revisions (i.e., the best grades) has a 23.3% backtested annual return since inception, whereas an example screen following those with the worst revisions has a backtested annual return since inception of under 5%.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the Quality Grade is the percentile rank of the composite return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F—Score.

These 3 key factors, when combined with the above, provide a holistic view into a stock. Further, by joining A+ Investor you can see whether Bone Biologics Corp’s stock passes any of our 60+ stock screens that have outperformed the market since their creation.

Is Bone Biologics Corp (BBLG) Stock a Good Investment? (5)

Should I Buy Bone Biologics Corp Stock?

Overall, Bone Biologics Corp stock has a Growth Grade of F, Momentum Grade of F .

Whether or not you should buy Bone Biologics Corp stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure these out and identify which investments align with what works best for you.

Lastly, it’s important to evaluate a stock by comparing it against others in the same industry. Review the table below to see how Bone Biologics Corp stock stands up against its competitors. Click into any of the below tickers to see their stock grades for value, momentum, quality and EPS revisions.

Bone Biologics Corp (BBLG) Competitors

Companies similar to Bone Biologics Corp in the Medical Equipment, Supplies & Distribution industry.

Company name Ticker Market Cap
SINTX Technologies Inc SINT $1.29Mil
Bluejay Diagnostics Inc BJDX $1.11Mil
NanoVibronix Inc NAOV $1.77Mil
Nemaura Medical Inc NMRD $2.31Mil
Invo Bioscience Inc INVO $2.72Mil

Bone Biologics Corp Stock: Bottom Line

You can use the information about how Bone Biologics Corp is graded to determine if you should invest in this stock. However, you should decide whether Bone Biologics Corp’s stock is a buy, sell or hold based on a combination of grades, metrics, ratios and U.S. Securities and Exchange Commission (SEC) reports.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets—without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

So, if you’re still on the fence about whether Bone Biologics Corp is a buy, sell or hold, you can utilize AAII’s expansive and robust screening tools like A+ Investor to help with your decision.

A+ Investor adds to its qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions, find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Is Bone Biologics Corp (BBLG) Stock a Good Investment? (6)


I am a seasoned financial analyst with a deep understanding of the stock market and investment strategies. Over the years, I have closely followed various industries and companies, staying abreast of market trends, financial metrics, and key investment factors. My expertise extends to evaluating stocks based on their value, growth potential, momentum, earnings revisions, and overall quality.

Now, let's delve into the information provided in the article about Bone Biologics Corp and related concepts.

  1. Market Capitalization and Financial Metrics: As of January 22, 2024, Bone Biologics Corp has a market capitalization of $1.7 million, placing it in the 5th percentile of companies in the Medical Equipment, Supplies & Distribution industry. The company currently has negative earnings over the last 12 trailing months, resulting in an insignificant P/E ratio. The trailing 12-month revenue stands at $0.0 million, with a % profit margin. Analysts project adjusted earnings to reach $-25.840 per share for the current fiscal year, and the company does not pay a dividend.

  2. Industry Trends: The article highlights the increasing demand for medical devices in recent years, driven by process innovations, emerging technology, and an aging population. The medical equipment industry is expected to benefit from coronavirus test sales, new product sales, and growing exposure in emerging markets. Companies selling coronavirus tests are anticipated to have strong sales as people return to offices and schools. Vaccine campaigns and the expectation of a recovery in elective procedure volumes also play a role in shaping industry dynamics.

  3. Long-Term Outlook for Medical Device Manufacturers: Analysts foresee positive fundamental trends for medical device manufacturers in the long term. These include global demand for cost-effective value-based healthcare, demographic shifts, and rising research and development (R&D) investments leading to innovative products and revenue growth.

  4. Stock Grading by A+ Investor: AAII's A+ Investor provides grades for Bone Biologics Corp based on five key investing factors: value, growth, momentum, earnings revisions, and quality. The Growth Grade for Bone Biologics Corp is F (Very Weak), indicating a lack of strong, consistent, and prolonged growth. The Momentum Grade is also F (Very Weak), suggesting low relative price strength over the specified period.

  5. Competitor Comparison: Bone Biologics Corp is compared to competitors in the Medical Equipment, Supplies & Distribution industry, including companies like SINTX Technologies Inc (SINT), Bluejay Diagnostics Inc (BJDX), NanoVibronix Inc (NAOV), Nemaura Medical Inc (NMRD), and Invo Bioscience Inc (INVO). The comparison includes market capitalization data for each competitor.

  6. Bottom Line and Investment Decision: The article concludes by emphasizing that investors should use the provided information about how Bone Biologics Corp is graded to determine whether to invest in the stock. The decision to buy, sell, or hold should be based on a combination of grades, metrics, ratios, and U.S. Securities and Exchange Commission (SEC) reports. Investors are encouraged to conduct their own due diligence and research.

In summary, the analysis provides a comprehensive overview of Bone Biologics Corp, its financial situation, industry trends, stock grading, and competitor comparison, assisting investors in making informed decisions.

Is Bone Biologics Corp (BBLG) Stock a Good Investment? (2024)

References

Top Articles
Latest Posts
Article information

Author: Barbera Armstrong

Last Updated:

Views: 6543

Rating: 4.9 / 5 (59 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Barbera Armstrong

Birthday: 1992-09-12

Address: Suite 993 99852 Daugherty Causeway, Ritchiehaven, VT 49630

Phone: +5026838435397

Job: National Engineer

Hobby: Listening to music, Board games, Photography, Ice skating, LARPing, Kite flying, Rugby

Introduction: My name is Barbera Armstrong, I am a lovely, delightful, cooperative, funny, enchanting, vivacious, tender person who loves writing and wants to share my knowledge and understanding with you.